Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

This study is being done to answer the following question: Can the chance of gastroesophageal cancer growing or spreading be lowered by adding a drug called zanidatamab to the usual combination of drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as care most people get for gastroesophageal cancer

NCT Number	NCT06043427
Lead Sponsor	Canadian Cancer Trials Group Collaborators: Jazz Pharmaceuticals
Conditions	Gastroesophageal Adenocarcinoma
Enrollment	168 participants
Start Date	2024-04-16
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-11